Interaction between Digoxin and Adenosine
Major Synergy

ID DDInter554 and DDInter31
Interaction The use of adenosine in patients receiving digitalis glycosides may increase the risk of ventricular fibrillation. Rare cases of ventricular fibrillation, including both resuscitated and fatal cases, have been reported following treatment with adenosine intravenous bolus injection for the rapid conversion of paroxysmal supraventricular tachycardias to a normal sinus rhythm. Most cases were associated with the concomitant use of digoxin or, less frequently, digoxin and verapamil. However, no causal relationship or drug-drug interaction has been established. Concomitant use of adenosine and digitalis glycosides may also increase the risk and/or severity of sinus bradycardia and heart block due to additive or synergistic depressant effects on the sinoatrial and atrioventricular nodes.
abdominal pain aortic regurgitation bronchial spasm pleural pain confusion dizziness drowsiness drug toxicity NOS dysarthria dyspepsia More
Management Adenosine should be used with caution in patients receiving digitalis glycosides. Adenosine should be discontinued immediately if angina, severe bradycardia, severe hypotension, or asystole occurs. Also, patients who develop high-level atrioventricular block on one dose of adenosine should not be given additional doses. Appropriate resuscitative measures should be readily available.
References
Alternative for Digoxin -
Alternative for Adenosine C01E

Potential Metabolism Interactions

Substrate-Substrate Interaction:If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction:Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction:Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.